BOSTON/LONDON (Reuters) – Human Genome Sciences Inc said its experimental lupus drug Benlysta eased symptoms in more than 43 percent of patients who took it in a clinical trial, paving the way for approval of the first new treatment for the disease in 50 years.

The rest is here:
Human Genome 2nd lupus trial succeeds